摘要
目的探讨吉西他滨和表柔比星在浅表性膀胱癌经尿道电切术后热灌注治疗中的应用效果。方法根据治疗方法的不同将90例浅表性膀胱癌患者分为对照组(n=44)和观察组(n=46),两组患者均接受经尿道膀胱肿瘤电切术(TURBT)治疗,对照组患者术后给予吉西他滨膀胱热灌注治疗,观察组患者术后给予表柔比星和吉西他滨序贯膀胱热灌注治疗。比较两组患者的炎症因子[可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和C反应蛋白(CRP)]水平、肿瘤标志物[重组人Dickkopf蛋白1(DKK1)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、血管内皮生长因子(VEGF)]水平、不良反应发生情况、术后复发情况及生活质量[膀胱癌特异性量表(BCI)]。结果术后1年,两组患者的sICAM-1、sVCAM-1、CRP、DKK1、CYFRA21-1、VEGF水平均低于本组术前,且观察组患者的sICAM-1、sVCAM-1、CRP、DKK1、CYFRA21-1、VEGF水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。术后1年,观察组患者的复发率低于对照组,差异有统计学意义(P﹤0.05)。术后1年,两组患者BCI量表各领域评分均高于本组术前,且观察组患者BCI量表各领域评分均高于对照组,差异均有统计学意义(P﹤0.05)。结论TURBT术后表柔比星和吉西他滨序贯膀胱热灌注治疗浅表性膀胱癌可高效杀灭肿瘤细胞,降低患者的炎症水平和术后复发率,提高生活质量。
Objective To investigate the application effect of gemcitabine and epirubicin in hyperthermic perfusion therapy after transurethral resection of superficial bladder tumor. Method A total of 90 patients with superficial bladder cancer were divided into control group(n=44) and observation group(n=46) according to the different treatment methods. Both groups received transurethral resection of bladder tumor(TURBT). The control group were given gemcitabine intravesical hyperthermic infusion therapy after the operation, and the observation group were given sequential intravesical hyperthermic infusion therapy with epirubicin and gemcitabine after the operation. The levels of inflammatory factors[soluble intercellular adhesion molecule-1(sICAM-1), soluble vascular cell adhesion molecule-1(sVCAM-1), and C-reactive protein(CRP)], tumor markers [recombinant human Dickkopf-related protein 1(DKK1), cyto-keratin 19 fragment antigen 21-1(CYFRA21-1), vascular endothelial growth factor(VEGF)] levels, the incidence of adverse events, postoperative recurrence and quality of life [bladder cancer specific inventory(BCI)] were compared between the two groups. RRee-sult One year after the operation, the levels of sICAM-1, sVCAM-1, CRP, DKK1, CYFRA21-1, and VEGF in the two groups were lower than those before the operation, and the levels of above indicators in the observation group were lower than those in the control group, and the differences were statistically significant(P<0.05). There was no significant difference in the total incidence of adverse events between the two groups(P>0.05). One year after the operation, the recurrence rate of the observation group was lower than that of the control group, and the difference was statistically significant(P<0.05). One year after the operation, the scores of all areas of the BCI scale in the two groups were higher than those before the operation, and the scores of all areas of the BCI scale in the observation group were higher than those in the control group, and the differences were sta
作者
桂琦
黄雪强
张奎
刘太阳
文秀华
GUI Qi;HUANG Xueqiang;ZHANG Kui;LIU Taiyang;WEN Xiuhua(Department of Urology Surgery,Zhumadian Central Hospital,Zhumadian 463000,He'nan,China)
出处
《癌症进展》
2022年第19期2007-2010,2014,共5页
Oncology Progress
关键词
浅表性膀胱癌
热灌注治疗
吉西他滨
表柔比星
应用效果
superficial bladder cancer
hyperthermic perfusion therapy
gemcitabine
epirubicin
application effect
